Physician profile
Theodore Doukides
NPI 1801063961
$2,743.42
in general payments reported to CMS, 2019-2025
26 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $326 · 2021: $245 · 2022: $139 · 2023: $316 · 2024: $632 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.23 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $559.22 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Boston Scientific Corporation | $526.77 | 2019-2025 | Wallflex Duodenal, General - Hemostasis |
| Janssen Biotech, INC. | $396.94 | 2020-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.97 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $124.46 | 2024 | Voquezna |
| Pentax of America, INC. | $111.79 | 2022-2024 | Inspira, Pentax Medical, C2 Cryoballoon |
| Intercept Pharmaceuticals, INC. | $96.24 | 2019-2025 | |
| Madrigal Pharmaceuticals | $85.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Shionogi INC | $77.59 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $53.77 | 2025 | Iqirvo |
| Medtronic, INC. | $50.88 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.00 | 2023-2025 | Entyvio |
| Axonics, INC. | $49.79 | 2024 | Axonics |
| Aimmune Therapeutics, INC. | $45.99 | 2024 | |
| Pfizer INC. | $38.41 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $33.80 | 2024-2025 | Pancreaze |
| Ironwood Pharmaceuticals, INC | $30.61 | 2024 | |
| Alnylam Pharmaceuticals INC. | $29.11 | 2022 | |
| Nestle Healthcare Nutrition INC. | $27.83 | 2023 | |
| Redhill Biopharma INC. | $24.71 | 2020 | |
| Ucb, INC. | $22.11 | 2019 | |
| Concordia Pharmaceuticals INC. | $19.58 | 2019 | |
| Alfasigma USA, INC. | $17.20 | 2020 | |
| Allergan, INC. | $16.74 | 2019 | |
| Ardelyx, INC. | $15.63 | 2024 | Ibsrela |
| Cook Medical LLC | $15.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Doukides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.